Antenatal Corticosteroid Therapy: Which Impact on Birth Parameters?
Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Nov 28, 2022
Trial Information
Current as of January 16, 2025
Completed
Keywords
ClinConnect Summary
All children included in the study were born at the Regional Maternity Hospital of Nancy between January 1, 2014 and December 31, 2020.
One hundred and twenty-one of them were exposed during pregnancy to antenatal corticosteroids therapy and constitute the exposed arm, whereas 242 were not and constitute the non-exposed arm.
Data were collected retrospectively regarding history of pregnancy, birth parameters and neonatal adaptation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all children exposed to an antenatal corticosteroid therapy before 34 weeks of amenorrhea because of a threat of premature delivery
- • only full-term newborns
- Exclusion Criteria:
- • all children exposed to an antenatal corticosteroid therapy before 34 weeks of amenorrhea for other reasons
About Central Hospital, Nancy, France
Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials